drugset / Trial / NCT01863225
Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia
Phase 2
Terminated
13 enrolled
Resverlogix Corp
South Australian Health and Medical Research Institute · collab
Non-randomizedSingle-groupOpen-labelBasic science
Summary
This study is designed to characterize the pharmacokinetics of multi-dose RVX000222 and atorvastatin and rosuvastatin when either statin is administered in combination with RVX000222 in subjects with dyslipidemia.
Timeline
- Start
- 2013-05
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apabetalone | Small molecule | 100 mg | — |
| Subject | Atorvastatin | Small molecule | 40 mg | — |
| Subject | Atorvastatin | Small molecule | 80 mg | — |
| Subject | Rosuvastatin | Small molecule | 20 mg | — |
| Subject | Rosuvastatin | Small molecule | 40 mg | — |